Belinda Ha

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. doi request reprint Hepatic safety profile of fosamprenavir-containing regimens in HIV-1-infected patients with or without hepatitis B or C coinfection
    B Ha
    GlaxoSmithKline, Research Triangle Park, NC 27708, USA
    HIV Clin Trials 13:171-7. 2012
  2. doi request reprint Virologic response and safety of the abacavir/lamivudine fixed-dose formulation as part of highly active antiretroviral therapy: analyses of six clinical studies
    Belinda Ha
    GlaxoSmithKline, Research Triangle Park, North Carolina, USA
    HIV Clin Trials 10:65-75. 2009
  3. pmc Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir
    L L Ross
    GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA
    J Antimicrob Chemother 65:307-15. 2010
  4. doi request reprint Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263)
    Lisa Ross
    GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    AIDS Res Hum Retroviruses 25:665-72. 2009
  5. doi request reprint A study of HIV provider attitudes toward HLA-B 5701 testing in the United States
    Maria E Watson
    GlaxoSmithKline, Research Triangle Park, North Carolina 27709 3398, USA
    AIDS Patient Care STDS 23:957-63. 2009

Detail Information

Publications5

  1. doi request reprint Hepatic safety profile of fosamprenavir-containing regimens in HIV-1-infected patients with or without hepatitis B or C coinfection
    B Ha
    GlaxoSmithKline, Research Triangle Park, NC 27708, USA
    HIV Clin Trials 13:171-7. 2012
    ..This post hoc analysis investigated the hepatic safety profile of fosampre-navir (FPV) in patients monoinfected with HIV or coinfected with HIV and hepatitis B (HbsAg positive) and/or hepatitis C (anti-HCV antibody positive)...
  2. doi request reprint Virologic response and safety of the abacavir/lamivudine fixed-dose formulation as part of highly active antiretroviral therapy: analyses of six clinical studies
    Belinda Ha
    GlaxoSmithKline, Research Triangle Park, North Carolina, USA
    HIV Clin Trials 10:65-75. 2009
    ....
  3. pmc Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir
    L L Ross
    GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA
    J Antimicrob Chemother 65:307-15. 2010
    ....
  4. doi request reprint Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263)
    Lisa Ross
    GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    AIDS Res Hum Retroviruses 25:665-72. 2009
    ..These data suggest that TAMs selection is a preferred resistance route of this combination, with zidovudine modulating the resistance pathway against selection for K65R...
  5. doi request reprint A study of HIV provider attitudes toward HLA-B 5701 testing in the United States
    Maria E Watson
    GlaxoSmithKline, Research Triangle Park, North Carolina 27709 3398, USA
    AIDS Patient Care STDS 23:957-63. 2009
    ..The results of this study suggest that HLA-B 5701 testing is easy to use in clinical practice and is a valuable tool to help reduce the risk of developing ABC HSR...